Addex Therapeutics

Addex Therapeutics is a clinical-stage pharmaceutical company focused on developing and commercializing novel, orally available small molecule drugs called allosteric modulators. These modulators are designed to treat neurological disorders by selectively targeting specific receptors in the brain, offering potentially greater efficacy and fewer side effects compared to traditional drugs. Addex has a diverse pipeline of clinical and preclinical programs, including candidates for post-stroke/TBI recovery, substance use disorder, and chronic cough.

The company has established partnerships with pharmaceutical giants like Janssen Pharmaceuticals and Indivior, as well as academic institutions and governmental organizations, to advance its research and development efforts. Addex's shares are traded on the SIX Swiss Exchange and NASDAQ Capital Market, demonstrating its commitment to bringing its innovative therapies to patients worldwide.

Addex Therapeutics is a clinical-stage pharmaceutical company dedicated to developing and commercializing a novel class of orally available small molecule drugs known as allosteric modulators for the treatment of neurological disorders. Addex's mission is to provide innovative and effective therapies for patients suffering from a range of neurological conditions, including substance use disorder, chronic cough, and brain injury recovery. The company is focused on developing its pipeline of clinical and pre-clinical stage drug candidates, with a particular emphasis on those targeting G-protein coupled receptors (GPCRs). Addex is committed to delivering best-in-class treatments with improved tolerability and efficacy compared to existing therapies, addressing unmet medical needs and providing a significant commercial opportunity for its innovative drug candidates.